Welcome back to the Pharmaceutical News, some generic market news today so please read on...
On 19th December 2011, Amgen and Watson Pharmaceuticals announced that they are to collaborate to develop and commercialise, on a worldwide basis, a number of oncology antibody biosimilars. The firms commented that the agreement underscored a shared belief that the development and commercialisation of biosimilar products would not follow a pure brand or generic model, and would require significant expertise, infrastructure and investment.
Under the terms of the agreement, Amgen will assume primary responsibility for developing, manufacturing and initially commercialising the products. Watson will contribute up to US$400 million in co-development costs over the course of development, including the provision of development support, and will share product development risks. In addition, Watson will contribute its expertise in the commercialisation and marketing of products in highly competitive specialty and generic markets, including helping effectively manage the lifecycle of the biosimilar products. The collaboration products are expected to be sold under a joint Amgen / Watson label. Watson will initially receive royalties and sales milestones from product revenues. The two firms commented that the collaboration would not pursue biosimilars of Amgen's proprietary products.
Please click on the link to read more articles like this; Generics News
No comments:
Post a Comment